Method, process or approach
This study has been approved by the institutional review board (IRB) of the University of Texas MD Anderson Cancer Center. The clinical and survival data of the study population (130 pancreatic cancer patients) was identified from a database that is prospectively maintained by the Department of Surgical Oncology at MD Anderson Cancer Center. A waiver of consent was granted for the use of their specimen information for research.
To identify new molecular markers for early diagnosis of pancreatic cancer and predictive markers for more effective treatment of pancreatic cancer, immunohistochemistry was used to examine expression of eIF2a, short for Eukaryotic Translation Initiation Factor 2a, and its phosphorylated …show more content…
Among the 130 pancreatic cancer samples and their paired normal pancreatic samples examined, 117 (90%) human pancreases cancer samples has high levels expresson of p-eIF2a, but only 78 (60%) human normal pancreatic tissue samples has high expression of p-eIF2a. The expression of p-eIF2a is significantly higher in pancreatic cancer samples than that in normal pancreatic tissue samples (p<0.001, Chi-square analysis). In addition the result from this study also showed that high p-eIF2a expression in pancreatic cancer samples correlates with decreased frequency of tumor metastasis to lymph node and less frequent recurrences after surgery. More importantly, the result from this study show that patients with pancreatic cancer whose tumor has high p-eIF2a expression has a longer survival than those whose tumor has low or loss of p-eIF2a expression. These data suggest that increased expression of p-eIF2a can not only be used as molecular marker for early diagnosis of pancreatic cancer, but also suggest that p-eIF2a expression in pancreatic cancer can be used as predictive marker to predict the clinical behavior and survival in pancreatic
This study has been approved by the institutional review board (IRB) of the University of Texas MD Anderson Cancer Center. The clinical and survival data of the study population (130 pancreatic cancer patients) was identified from a database that is prospectively maintained by the Department of Surgical Oncology at MD Anderson Cancer Center. A waiver of consent was granted for the use of their specimen information for research.
To identify new molecular markers for early diagnosis of pancreatic cancer and predictive markers for more effective treatment of pancreatic cancer, immunohistochemistry was used to examine expression of eIF2a, short for Eukaryotic Translation Initiation Factor 2a, and its phosphorylated …show more content…
Among the 130 pancreatic cancer samples and their paired normal pancreatic samples examined, 117 (90%) human pancreases cancer samples has high levels expresson of p-eIF2a, but only 78 (60%) human normal pancreatic tissue samples has high expression of p-eIF2a. The expression of p-eIF2a is significantly higher in pancreatic cancer samples than that in normal pancreatic tissue samples (p<0.001, Chi-square analysis). In addition the result from this study also showed that high p-eIF2a expression in pancreatic cancer samples correlates with decreased frequency of tumor metastasis to lymph node and less frequent recurrences after surgery. More importantly, the result from this study show that patients with pancreatic cancer whose tumor has high p-eIF2a expression has a longer survival than those whose tumor has low or loss of p-eIF2a expression. These data suggest that increased expression of p-eIF2a can not only be used as molecular marker for early diagnosis of pancreatic cancer, but also suggest that p-eIF2a expression in pancreatic cancer can be used as predictive marker to predict the clinical behavior and survival in pancreatic